Related Experiment Video

Updated: May 18, 2026

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
12:21

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy

Bader Mohamad Al-Ali1, Anna Lena Ress, Armin Gerger

  • 1Department of Urology, Medical University of Graz, Graz, Austria.

Anticancer Research
|September 21, 2012
PubMed

Insights

Renal cell carcinoma (RCC) is treatable if caught early. MicroRNAs show promise as new tools for diagnosing, predicting, and treating this kidney cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Renal cell carcinoma (RCC) is a kidney cancer with variable outcomes.
  • Predicting complications and long-term effects of RCC remains challenging.
  • Current treatments are based on past molecular insights, necessitating advancements.

Purpose of the Study:

  • To review the role of microRNAs in renal cell carcinoma pathogenesis.
  • To explore microRNAs as potential diagnostic and prognostic biomarkers for RCC.
  • To discuss the therapeutic potential of microRNAs in managing RCC.

Main Methods:

  • Literature review of microRNA research in renal cell carcinoma.
  • Analysis of studies on microRNA involvement in cancer metastasis.
  • Synthesis of current understanding of microRNAs in RCC development and progression.

Main Results:

  • MicroRNAs play significant roles in the metastatic spread of tumor cells.
  • Evidence suggests microRNAs are implicated in the pathogenesis of RCC.
  • MicroRNAs demonstrate potential as biomarkers for RCC diagnosis and prognosis.

Conclusions:

  • MicroRNAs are critical in RCC pathogenesis and metastasis.
  • MicroRNAs offer potential as novel diagnostic and prognostic tools for RCC.
  • Further research into microRNAs could lead to new therapeutic strategies for RCC.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...